AntiCancer Inc, San Diego, CA, U.S.A.
Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan.
In Vivo. 2021 Nov-Dec;35(6):3107-3110. doi: 10.21873/invivo.12605.
BACKGROUND/AIM: Primary osteosarcoma of the mammary gland is a very rare disease, accounting for less than 1% of all mammary malignancies. There is no established first-line treatment and the prognosis is poor compared to normal breast cancer. We previously established the first patient tumor-derived animal model of this disease, grown subcutaneously in nude mice. In the present study, we established a patient derived orthotopic xenograft (PDOX) model of osteosarcoma of the breast and investigated the efficacy of cisplatinum (CDDP) and eribulin (ERB).
PDOX models of primary osteosarcoma of the breast were divided into 3 groups (5-6 mice per group): untreated control; CDDP treatment; ERB treatment. The tumor volume in the 3 groups was compared after 2 weeks.
There were significant differences between control and CDDP, and control and ERB (p=0.036, 0.046, respectively). However, there was no significant difference between CDDP and ERB (p=0.964).
CDDP and ERB are candidates for first-line clinical therapy of primary osteosarcoma of the breast.
背景/目的：原发性乳腺骨肉瘤是一种非常罕见的疾病，占所有乳腺恶性肿瘤的比例不到 1%。目前尚无明确的一线治疗方法，与普通乳腺癌相比，预后较差。我们之前建立了该疾病的首个患者肿瘤衍生的动物模型，在裸鼠的皮下生长。在本研究中，我们建立了原发性乳腺骨肉瘤的患者来源的原位异种移植（PDOX）模型，并研究了顺铂（CDDP）和艾瑞布林（ERB）的疗效。
将原发性乳腺骨肉瘤的 PDOX 模型分为 3 组（每组 5-6 只小鼠）：未治疗对照组；CDDP 治疗组；ERB 治疗组。2 周后比较 3 组的肿瘤体积。
对照组与 CDDP 组和对照组与 ERB 组之间存在显著差异（p=0.036，0.046）。然而，CDDP 组和 ERB 组之间无显著差异（p=0.964）。
CDDP 和 ERB 是原发性乳腺骨肉瘤一线临床治疗的候选药物。
